Journal ArticleDOI
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study
Gurkirpal Singh,John G. Fort,Jay L. Goldstein,Roger A. Levy,Patrick S. Hanrahan,Alfonso E. Bello,Lilia Andrade-Ortega,Carl B. Wallemark,Naurang M. Agrawal,Glenn M. Eisen,William F. Stenson,George Triadafilopoulos +11 more
TLDR
In the treatment of osteoarthritis, celecoxib is as effective as the nonspecific NSAIDs naproxen and diclofenac, but has significantly fewer serious upper gastrointestinal events.About:
This article is published in The American Journal of Medicine.The article was published on 2006-03-01. It has received 343 citations till now. The article focuses on the topics: Rofecoxib & Celecoxib.read more
Citations
More filters
Journal ArticleDOI
Pharmacological Management of Persistent Pain in Older Persons
Bruce A. Ferrell,Charles Argoff,J. Epplin,Perry G. Fine,F. M. Gloth,Keela Herr,J. D. Katz,D. R. Mehr,M. C. Reid,Lori Reisner,S. Radcliff,K. Addleman,C. Fierstein,E. Ickowicz,N. Lundebjerg +14 more
Journal ArticleDOI
Gastric Mucosal Defense and Cytoprotection: Bench to Bedside
TL;DR: Conditions in which mucosal injury is directly related to impairment in mucosal defense are discussed, focusing on disorders with important clinical sequelae: nonsteroidal anti-inflammatory drug (NSAID)-associated injury, which is primarily related to inhibition of cyclooxygenase-mediated PG synthesis, and stress-related mucosal disease (SRMD), which occurs with local ischemia.
Journal ArticleDOI
Pharmacological Management of Persistent Pain in Older Persons
E. Ickowicz,Bruce A. Ferrell,Charles Argoff,J. Epplin,Perry G. Fine,F. M. Gloth,Keela Herr,J. D. Katz,D. R. Mehr,M. C. Reid,Lori Reisner,C. Fierstein,N. Lundebjerg +12 more
TL;DR: In this paper, both appropriate and inappropriate medica- tions for older adults are detailed, as well as their contraindications and potential drug-drug or drug-disease interactions.
Journal ArticleDOI
Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract
TL;DR: Patients at-risk of NSAIDs should be considered for alternatives to NSAID therapy and modifications of risk factors, including co-therapy of NSAID with gastroprotectants (PPI or misoprostol) or the prescription of COX-2 selective inhibitors.
Journal ArticleDOI
An evidence-based update on nonsteroidal anti-inflammatory drugs.
TL;DR: This review will provide an educational update on the current evidence of the efficacy and adverse effects of NSAIDs, and an algorithm is proposed which delineates a general decision-making tree to select the most appropriate analgesic for an individual patient based on the evidence reviewed.
References
More filters
Journal Article
Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee.
TL;DR: WOMAC is a disease-specific purpose built high performance instrument for evaluative research in osteoarthritis clinical trials and fulfil conventional criteria for face, content and construct validity, reliability, responsiveness and relative efficiency.
Journal ArticleDOI
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier,Loren Laine,Alise S. Reicin,Deborah R. Shapiro,Ruben Burgos-Vargas,Barry R. Davis,Richard O. Day,Marcos Bosi Ferraz,Christopher J. Hawkey,Marc C. Hochberg,Tore K Kvien,Thomas J. Schnitzer +11 more
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Journal ArticleDOI
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
Robert S. Bresalier,Robert S. Sandler,Hui Quan,James A. Bolognese,Bettina Oxenius,Kevin J. Horgan,Christopher Lines,Robert H. Riddell,Dion Morton,Angel Lanas,Marvin A. Konstam,John A. Baron +11 more
TL;DR: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.
Journal ArticleDOI
Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Scott D. Solomon,John J.V. McMurray,Marc A. Pfeffer,Janet Wittes,Robert A. Fowler,Peter V. Finn,William F. Anderson,Ann G. Zauber,Ernest T. Hawk,Monica M. Bertagnolli +9 more
TL;DR: Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure, providing further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.